Brian Piekos - Jun 1, 2023 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role: Chief Financial Officer
Signature: /s/ Nishant M. Dharia, Attorney-in-fact
Stock symbol: ELTX
Transactions as of: Jun 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/5/2023, 05:25 PM
Previous filing: Jun 2, 2022
Next filing: Feb 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELTX	Stock Option (right to buy)	Award	$0	+75.5K		$0.00	75.5K	Jun 1, 2023	Common Stock	75.5K	$10.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 25% of the option shares on May 15, 2024 with the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to the Reporting Person continuing to provide services to the Issuer through the applicable vesting dates, and provided that in the event there is a change in control of the Issuer, followed by a subsequent termination of the Reporting Person's employment without cause (or a material diminishment of his role) within 12 months of the change of control, any unvested options granted will immediately vest.

Content

The option vests as to 25% of the option shares on May 15, 2024 with the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to the Reporting Person continuing to provide services to the Issuer through the applicable vesting dates, and provided that in the event there is a change in control of the Issuer, followed by a subsequent termination of the Reporting Person's employment without cause (or a material diminishment of his role) within 12 months of the change of control, any unvested options granted will immediately vest.